title: An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies.
abstract: Hepatitis C virus (HCV) circulates in the bloodstream in different forms, including complexes with immunoglobulins and/or lipoproteins. To address the significance of such associations, we produced or treated HCV pseudoparticles (HCVpp), a valid model of HCV cell entry and its inhibition, with naïve or patient-derived sera. We demonstrate that infection of hepatocarcinoma cells by HCVpp is increased more than 10-fold by human serum factors, of which high-density lipoprotein (HDL) is a major component. Infection enhancement requires scavenger receptor BI, a molecule known to mediate HDL uptake into cells as well as HCVpp entry, and involves conserved amino acid positions in hypervariable region 1 (HVR1) of the E2 glycoprotein. Additionally, we show that the interaction with human serum or HDL, but not with low-density lipoprotein, leads to the protection of HCVpp from neutralizing antibodies, including monoclonal antibodies and antibodies present in patient sera. Finally, the deletion or mutation of HVR1 in HCVpp abolishes infection enhancement and leads to increased sensitivity to neutralizing antibodies/sera compared to that of parental HCVpp. Altogether, these results assign to HVR1 new roles which are complementary in helping HCV to survive within its host. Besides immune escape by mutation, HRV1 can mediate the enhancement of cell entry and the protection of virions from neutralizing antibodies. By preserving a balance between these functions, HVR1 may be essential for the viral persistence of HCV.
authors.affiliation: Laboratoire de Vectorologie Rétrovirale et Thérapie Génique, INSERM U412, Ecole Normale Supérieure de Lyon, IFR128 BioSciences Lyon-Gerland, Lyon, France.
authors.forename: Birke
authors.initials: B
authors.lastname: Bartosch
authors.forename: Géraldine
authors.initials: G
authors.lastname: Verney
authors.forename: Marlène
authors.initials: M
authors.lastname: Dreux
authors.forename: Peggy
authors.initials: P
authors.lastname: Donot
authors.forename: Yoann
authors.initials: Y
authors.lastname: Morice
authors.forename: François
authors.initials: F
authors.lastname: Penin
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Pawlotsky
authors.forename: Dimitri
authors.initials: D
authors.lastname: Lavillette
authors.forename: Francois-Loïc
authors.initials: FL
authors.lastname: Cosset
mesh_terms: D006528:Carcinoma, Hepatocellular; D002460:Cell Line; D045744:Cell Line, Tumor; D022801:Complementarity Determining Regions / Q000235:genetics* / Q000378:metabolism; D016174:Hepacivirus / Q000235:genetics / Q000502:physiology*; D006526:Hepatitis C / Q000097:blood; D018937:Hepatitis C Antibodies / Q000276:immunology; D006801:Humans; D008075:Lipoproteins, HDL / Q000097:blood*; D008113:Liver Neoplasms; D016297:Mutagenesis, Site-Directed; D017354:Point Mutation; D011994:Recombinant Proteins / Q000378:metabolism; D014759:Viral Envelope Proteins / Q000235:genetics / Q000378:metabolism*
chemical_list: D022801:Complementarity Determining Regions; D018937:Hepatitis C Antibodies; D008075:Lipoproteins, HDL; D011994:Recombinant Proteins; D014759:Viral Envelope Proteins; C091015:glycoprotein E2, Hepatitis C virus